Related references
Note: Only part of the references are listed.Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
Leo Y. Y. Lee et al.
PLOS PATHOGENS (2021)
Baloxavir Treatment Delays Influenza B Virus Transmission in Ferrets and Results in Limited Generation of Drug-Resistant Variants
Philippe Noriel Q. Pascua et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza
Takeki Uehara et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
Nobuo Hirotsu et al.
CLINICAL INFECTIOUS DISEASES (2020)
Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains
Liva Checkmahomed et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets
Masaki Imai et al.
NATURE MICROBIOLOGY (2020)
A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions
Paulina Koszalka et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2020)
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility
Jeremy C. Jones et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice
Yacine Abed et al.
ANTIVIRAL RESEARCH (2020)
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial
Michael G Ison et al.
LANCET INFECTIOUS DISEASES (2020)
Influenza and antiviral resistance: an overview
Temi Lampejo
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2020)
In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors
Clement Fage et al.
VIRUSES-BASEL (2019)
Susceptibility of Influenza A, B, and D Viruses to Baloxavir
Vasiliy P. Mishin et al.
EMERGING INFECTIOUS DISEASES (2019)
Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018
Danuta M. Skowronski et al.
EUROSURVEILLANCE (2018)
Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: A systematic literature review
Saverio Caini et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2018)
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
A. Danielle Iuliano et al.
LANCET (2018)
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
Shinya Omoto et al.
SCIENTIFIC REPORTS (2018)
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Frederick G. Hayden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
Takeshi Noshi et al.
ANTIVIRAL RESEARCH (2018)
Adamantane-Resistant Influenza A Viruses in the World (1902-2013): Frequency and Distribution of M2 Gene Mutations
Guoying Dong et al.
PLOS ONE (2015)
Influenza virus resistance to neuraminidase inhibitors
Melanie Samson et al.
ANTIVIRAL RESEARCH (2013)
Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance
Jennifer L. McKimm-Breschkin
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2013)
Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata city, Japan
Maki Sato et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza a infection in children
Norio Sugaya et al.
CLINICAL INFECTIOUS DISEASES (2007)
Recovery of drug-resistant influenza virus from immunocompromised patients: A case series
MG Ison et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Mechanism by which mutations at His274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir
MZ Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo
J Carr et al.
ANTIVIRAL RESEARCH (2002)
Share Paper
